Related Experiment Video

Updated: May 20, 2026

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
08:55

Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats

Published on: April 15, 2016

[Construction and application of a noval gene-target therapy system in hepatocellular carcinoma]

Gewen Zhang1, Ting Liu, Zhiming Wang

  • 1Department of General Surgery, Xiangya Hospital, Central South University, Changsha 410008, China.

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi = Journal of Biomedical Engineering = Shengwu Yixue Gongchengxue Zazhi
|July 26, 2012
PubMed

Insights

A novel gene therapy system effectively targets hepatocellular carcinoma (HCC) cells by silencing survivin. This approach shows high efficiency in inhibiting HCC cell growth and inducing cell death, offering a promising new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Hepatocellular carcinoma (HCC) remains a significant global health challenge with limited effective treatment options.
  • Survivin is a key protein involved in cell proliferation and apoptosis, making it a potential therapeutic target in HCC.
  • Developing targeted gene therapy strategies is crucial for improving HCC treatment outcomes.

Purpose of the Study:

  • To explore the efficiency of a novel gene-targeting therapy system for hepatocellular carcinoma (HCC) treatment in vitro.
  • To utilize a new fusion promoter (AV) for specific gene expression in HCC cells.
  • To evaluate the therapeutic potential of targeting the survivin gene in HCC.

Main Methods:

  • Construction of a novel eukaryotic expression plasmid (pcDNA3.1(-)AV) containing a fusion promoter (AV) and gene of interest (GFP or siRNA-survivin).
  • Transfection of HCC cell lines (HepG2, SMMC-7721) and a control cell line (Hela) using calcium phosphate nanoparticles.
  • Assessment of transfection efficiency via GFP expression, gene knockdown via RT-PCR and Western blot, and cell viability/death using MTT assay and flow cytometry.

Main Results:

  • The AV promoter demonstrated specific gene expression in HCC cells (HepG2) but not in Hela cells, confirming targeted delivery.
  • Transfection with pcDNA3.1(-)AVsiRNA-survivin significantly silenced survivin mRNA and protein expression in HepG2 cells.
  • HepG2 cells treated with the survivin-targeting system exhibited a 68.8% increase in cell death (apoptosis and necrosis) and significant growth inhibition.

Conclusions:

  • The novel gene-targeting therapy system exhibits high efficiency and specificity in targeting HCC cells.
  • Silencing survivin using this system effectively inhibits HCC cell growth and induces cell death.
  • This approach represents a promising new gene therapy strategy for the treatment of hepatocellular carcinoma.

More Related Videos

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine09:54

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine

Published on: November 4, 2018

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery07:25

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery

Published on: August 18, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...